| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/13/2013 | US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents |
| 06/13/2013 | US20130149399 Skin temperature elevating agent, and cosmetic composition, food and sundry article containing the same |
| 06/13/2013 | US20130149393 Medical compositions containing liquorice extracts with synergistic effect |
| 06/13/2013 | US20130149392 Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| 06/13/2013 | US20130149383 Sustained release particle formulations of guaifenesin |
| 06/13/2013 | US20130149379 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 06/13/2013 | US20130149378 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof |
| 06/13/2013 | US20130149374 Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same |
| 06/13/2013 | US20130149369 Composition for nucleic acid transfection |
| 06/13/2013 | US20130149362 Treatment product and method |
| 06/13/2013 | US20130149361 Encapsulated pink tourmaline for skin |
| 06/13/2013 | US20130149355 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 06/13/2013 | US20130149352 Apparatus and method for the treatment of abnormal uterine bleeding |
| 06/13/2013 | US20130149345 Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| 06/13/2013 | US20130149344 Pleasure Enhancing Condom |
| 06/13/2013 | US20130149341 Methods of improving skin quality |
| 06/13/2013 | US20130149320 Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer |
| 06/13/2013 | US20130149319 Anticancer composition |
| 06/13/2013 | US20130149314 p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth |
| 06/13/2013 | US20130149312 Compositions and methods for treating copd exacerbation |
| 06/13/2013 | US20130149311 Gfi1b modulation and uses thereof |
| 06/13/2013 | US20130149310 Compositions for the treatment of rheumatoid arthritis and methods of using same |
| 06/13/2013 | US20130149309 Novel regulatory proteins and inhibitors |
| 06/13/2013 | US20130149307 Humanized anti-egfl7 antibodies and methods using same |
| 06/13/2013 | US20130149305 Soluble cd80 as a therapeutic to reverse immune supression in cancer patients |
| 06/13/2013 | US20130149302 Therapeutic agents for pancreatic cancer |
| 06/13/2013 | US20130149299 Dosages for treatment with anti-egfr antibodies |
| 06/13/2013 | US20130149296 Salts of Isophosphoramide Mustard and Analogs Thereof As Anti-Tumor Agents |
| 06/13/2013 | US20130149295 Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease |
| 06/13/2013 | US20130149291 Production and use of bacterial histamine |
| 06/13/2013 | US20130149283 Methods and compositions for treating hepatitis c virus |
| 06/13/2013 | US20130149277 Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| 06/13/2013 | US20130149257 Antimicrobial compositions |
| 06/13/2013 | US20130149255 Vitamin b12 compositions |
| 06/13/2013 | US20130149253 Oral dosage form of pregabalin |
| 06/13/2013 | US20130146481 Bioactive compositions from theacea plants and processes for their production and use |
| 06/13/2013 | DE102013205049A1 Antioxidant composition useful e.g. as agent for treating and/or preventing stress-related illnesses and for increasing mental performance, comprises polyphenol-rich plant extract, porphyrin, and additional compound including stilbenoids |
| 06/13/2013 | DE102011122236A1 Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives |
| 06/13/2013 | DE102011088270A1 (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot (11ß, 17ß) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Crohn's Charcot Marie toot |
| 06/13/2013 | DE102011087987A1 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln 6,7-dihydro-5H-benzo [7] annulene derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use for the preparation of medicaments |
| 06/13/2013 | DE102011056142A1 Metabolisierbare Salze und deren Verwendung in Diagnostik und Therapie Metabolizable salts and their use in diagnosis and therapy |
| 06/13/2013 | CA2877423A1 Application of fluoxetine to treatment of depigmentation diseases |
| 06/13/2013 | CA2858752A1 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| 06/13/2013 | CA2858576A1 Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| 06/13/2013 | CA2858571A1 Composition and method for neuropeptide s receptor (npsr) antagonists |
| 06/13/2013 | CA2858570A1 Methods and compositions for alteration of skin pigmentation |
| 06/13/2013 | CA2858561A1 Biocidal compositions and methods of using the same |
| 06/13/2013 | CA2858522A1 Methods for treating cardiovascular disorder |
| 06/13/2013 | CA2858478A1 Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing |
| 06/13/2013 | CA2858447A1 Kinase inhibitors |
| 06/13/2013 | CA2858420A1 Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
| 06/13/2013 | CA2858382A1 Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods |
| 06/13/2013 | CA2858364A1 Oral spray formulations and methods for administration of sildenafil |
| 06/13/2013 | CA2858342A1 Phenylpyrrole derivative |
| 06/13/2013 | CA2858316A1 Multicomponent crystalline system of voriconazole with fumaric acid |
| 06/13/2013 | CA2858312A1 Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants |
| 06/13/2013 | CA2858265A1 6,7-dihydro-5h-benzo[7]annulene derivatives, methods for the production thereof, pharmaceutical preparations that contain said 6,7-dihydro-5h-benzo[7]annulene derivatives, and use thereof to produce drugs |
| 06/13/2013 | CA2858234A1 Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules |
| 06/13/2013 | CA2858164A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | CA2858161A1 Medical organogel processes and compositions |
| 06/13/2013 | CA2858012A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/13/2013 | CA2858011A1 Compositions for photodynamic therapy chemically modified to increase epithelia penetration and cellular bioavailability |
| 06/13/2013 | CA2857990A1 Oral formulations for treating metal overload |
| 06/13/2013 | CA2857231A1 Skin anti-ageing composition |
| 06/13/2013 | CA2857198A1 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists |
| 06/13/2013 | CA2857189A1 Topical formulation for administering a compound |
| 06/13/2013 | CA2857109A1 Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| 06/13/2013 | CA2857096A1 Process for recovery of nalmefene hydrochloride |
| 06/13/2013 | CA2856654A1 Hydantoin derivatives useful as kv3 inhibitors |
| 06/13/2013 | CA2856607A1 Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| 06/13/2013 | CA2856364A1 Vectors harboring toxic genes, methods and uses therefor |
| 06/13/2013 | CA2856043A1 Nasal formulation |
| 06/13/2013 | CA2855994A1 Phosphate esters of noribogaine |
| 06/13/2013 | CA2855990A1 Sulfate esters of noribogaine |
| 06/13/2013 | CA2855351A1 Novel pyrrole derivatives |
| 06/13/2013 | CA2854603A1 Inhibitors of bruton's tyrosine kinase |
| 06/13/2013 | CA2853891A1 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/13/2013 | CA2853500A1 Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
| 06/13/2013 | CA2852366A1 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/12/2013 | EP2602322A1 Induction of exon skipping in eukaryotic cells |
| 06/12/2013 | EP2602260A1 Process for preparing compound having hiv integrase inhibitory activity |
| 06/12/2013 | EP2602259A2 Salt of proline derivative, solvate thereof, and production method thereof |
| 06/12/2013 | EP2602255A1 Fused heterocyclic ring compound |
| 06/12/2013 | EP2602254A1 Heterocyclic compound |
| 06/12/2013 | EP2602253A1 Crystal of anti-bacterial compound |
| 06/12/2013 | EP2602252A1 Pyridazine derivatives and use thereof as medicaments for treating microrna viral infection |
| 06/12/2013 | EP2602249A1 Synthesis of rosuvastatin by means of co-crystals |
| 06/12/2013 | EP2602248A1 Novel pyrrole compounds |
| 06/12/2013 | EP2602242A1 Process for preparing compound by novel sandmeyer-like reaction using nitroxide radical compound as reaction catalyst |
| 06/12/2013 | EP2601981A1 Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| 06/12/2013 | EP2601971A1 Composition for regeneratng normal tissue from fibrotic tissue |
| 06/12/2013 | EP2601964A1 Balanol compounds for use in treating pain |
| 06/12/2013 | EP2601962A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/12/2013 | EP2601961A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/12/2013 | EP2601959A1 Elastase inhibitor |
| 06/12/2013 | EP2601958A1 Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
| 06/12/2013 | EP2601954A1 Therapeutic agent for disease |
| 06/12/2013 | EP2601953A1 Carbostyril derivatives and mood stabilizers for treating mood disorders |
| 06/12/2013 | EP2601952A1 Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
| 06/12/2013 | EP2601951A1 Pharmaceutical composition for treating hemorrhage caused by blood clotting disorder and use thereof |